CliffBio
biologic

Synagis

palivizumab

Loss of exclusivityJuly 2016projected — 12-year biologic exclusivity estimate
CompanySwedish Orphan Biovitrum AB (publ)

Drug detail

Brand nameSynagis
Active ingredientpalivizumab
Strength50MG/0.5ML
Dosage formInjection
RouteIntramuscular
ModalityBiologic
FDA approvalJuly 2004
Marketing statusRx

More from Swedish Orphan Biovitrum AB (publ)

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Synagis patent cliff — loss of exclusivity July 2016 | CliffBio